CHD4 and breast carcinoma: Notably, CHD4 silencing significantly reduced in vivo growth (80%) (Figure 3E), confirming the role of CHD4 in growth maintenance of two different metastatic breast cancer subtypes and suggesting that CHD4 can be a potential druggable target also for the most aggressive diseases.